Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
(WorldNews Europe)

Sunday, December 8, 2019 - 15:00 Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) (`Innate` or the `Company`) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine. The final analysis showed that 36 percent (29/80) of the relapsed or refractory hairy cell...